343 related articles for article (PubMed ID: 25212883)
1. Diagnosis and risk stratification in multiple myeloma.
van de Donk NW; Sonneveld P
Hematol Oncol Clin North Am; 2014 Oct; 28(5):791-813. PubMed ID: 25212883
[TBL] [Abstract][Full Text] [Related]
2. Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
Kyle RA; San-Miguel JF; Mateos MV; Rajkumar SV
Hematol Oncol Clin North Am; 2014 Oct; 28(5):775-90. PubMed ID: 25212882
[TBL] [Abstract][Full Text] [Related]
3. Insights from the gene expression profiling of multiple myeloma.
Claudio JO; Masih-Khan E; Stewart AK
Curr Hematol Rep; 2004 Jan; 3(1):67-73. PubMed ID: 14695854
[TBL] [Abstract][Full Text] [Related]
4. Multiple myeloma--an update on diagnosis and treatment.
Caers J; Vande broek I; De Raeve H; Michaux L; Trullemans F; Schots R; Van Camp B; Vanderkerken K
Eur J Haematol; 2008 Nov; 81(5):329-43. PubMed ID: 18637123
[TBL] [Abstract][Full Text] [Related]
5. Abnormal cytogenetics predict poor survival after high-dose therapy and autologous blood cell transplantation in multiple myeloma.
Rajkumar S; Fonseca R; Lacy M; Witzig T; Lust J; Greipp P; Therneau T; Kyle R; Litzow M; Gertz M
Bone Marrow Transplant; 1999 Sep; 24(5):497-503. PubMed ID: 10482933
[TBL] [Abstract][Full Text] [Related]
6. Molecular pathogenesis of multiple myeloma: chromosomal aberrations, changes in gene expression, cytokine networks, and the bone marrow microenvironment.
Klein B; Seckinger A; Moehler T; Hose D
Recent Results Cancer Res; 2011; 183():39-86. PubMed ID: 21509680
[TBL] [Abstract][Full Text] [Related]
7. [Multiple myeloma].
Krome S
Dtsch Med Wochenschr; 2012 Mar; 137 Suppl 1():S14-7. PubMed ID: 22438117
[No Abstract] [Full Text] [Related]
8. [Prognostic value of the ratio of bone marrow plasma cells in multiple myeloma].
Pasqualetti P; Colantonio D; Casale R
Minerva Med; 1990 Mar; 81(3):129-33. PubMed ID: 2320280
[TBL] [Abstract][Full Text] [Related]
9. IgM myeloma: A multicenter retrospective study of 134 patients.
Castillo JJ; Jurczyszyn A; Brozova L; Crusoe E; Czepiel J; Davila J; Dispenzieri A; Eveillard M; Fiala MA; Ghobrial IM; Gozzetti A; Gustine JN; Hajek R; Hungria V; Jarkovsky J; Jayabalan D; Laubach JP; Lewicka B; Maisnar V; Manasanch EE; Moreau P; Morgan EA; Nahi H; Niesvizky R; Paba-Prada C; Pika T; Pour L; Reagan JL; Richardson PG; Shah J; Spicka I; Vij R; Waszczuk-Gajda A; Gertz MA
Am J Hematol; 2017 Aug; 92(8):746-751. PubMed ID: 28383205
[TBL] [Abstract][Full Text] [Related]
10. Defining IgM multiple myeloma.
Owen RG; Feyler S; O'Connor SJ; Bond LR; de Tute RM; Rawstron AC
Am J Hematol; 2011 Aug; 86(8):717; author reply 718-9. PubMed ID: 21761439
[No Abstract] [Full Text] [Related]
11. The prognostic value of diagnosing concurrent multiple myeloma in immunoglobulin light chain amyloidosis.
Dinner S; Witteles W; Witteles R; Lam A; Arai S; Lafayette R; George TI; Schrier SL; Liedtke M
Br J Haematol; 2013 May; 161(3):367-72. PubMed ID: 23432783
[TBL] [Abstract][Full Text] [Related]
12. Bone marrow trephine biopsy findings in myeloma with small-lymphoid cells and CCND1 translocation.
Abdalla S; May PC; Garimberti E; Naresh KN
Am J Hematol; 2011 Dec; 86(12):1038. PubMed ID: 21898528
[No Abstract] [Full Text] [Related]
13. Gene expression profiling defines a high-risk entity of multiple myeloma.
Zhan FH; Barlogie B; John D S
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2007 Apr; 32(2):191-203. PubMed ID: 17478923
[TBL] [Abstract][Full Text] [Related]
14. Prognostic indicators for the diagnosis of multiple myeloma.
Greipp P;
Oncology (Williston Park); 2004 May; 18(5):558-60. PubMed ID: 15209186
[TBL] [Abstract][Full Text] [Related]
15. Increased copy number of the interleukin-6 receptor gene is associated with adverse survival in multiple myeloma patients treated with autologous stem cell transplantation.
Kim SY; Min HJ; Park HK; Oh B; Kim TY; She CJ; Hwang SM; Kim M; Kim HK; Kim I; Yoon SS; Park S; Kim BK; Lee JH; Lee DS;
Biol Blood Marrow Transplant; 2011 Jun; 17(6):810-20. PubMed ID: 21220034
[TBL] [Abstract][Full Text] [Related]
16. Detection of genomic abnormalities in multiple myeloma: the application of FISH analysis in combination with various plasma cell enrichment techniques.
Hartmann L; Biggerstaff JS; Chapman DB; Scott JM; Johnson KR; Ghirardelli KM; Fritschle WK; Martinez DL; Bennington RK; de Baca ME; Wells DA; Loken MR; Zehentner BK
Am J Clin Pathol; 2011 Nov; 136(5):712-20. PubMed ID: 22031309
[TBL] [Abstract][Full Text] [Related]
17. IgM multiple myeloma: more on a rare and heterogeneous disease.
Cabrera Q; Chantepie S; Salaun V; Levaltier X; Troussard X; Macro M
Am J Hematol; 2011 Aug; 86(8):717-8; author reply 718-9. PubMed ID: 21630314
[No Abstract] [Full Text] [Related]
18. Prognostic factors associated with progression of smoldering multiple myeloma to symptomatic form.
Rago A; Grammatico S; Za T; Levi A; Mecarocci S; Siniscalchi A; De Rosa L; Felici S; Bongarzoni V; Piccioni AL; La Verde G; Pisani F; Franceschini L; Paviglianiti AL; Caravita T; Petrucci MT; De Stefano V; Cimino G;
Cancer; 2012 Nov; 118(22):5544-9. PubMed ID: 22786730
[TBL] [Abstract][Full Text] [Related]
19. Relationship of P-selectin glycoprotein ligand-1 to prognosis in patients with multiple myeloma.
Atalay F; Ateşoğlu EB; Yıldız S; Firatlı-Tuglular T; Karakuş S; Bayık M
Clin Lymphoma Myeloma Leuk; 2015 Mar; 15(3):164-70. PubMed ID: 25445472
[TBL] [Abstract][Full Text] [Related]
20. Circulating Serum MicroRNA-130a as a Novel Putative Marker of Extramedullary Myeloma.
Besse L; Sedlarikova L; Kryukov F; Nekvindova J; Radova L; Slaby O; Kuglik P; Almasi M; Penka M; Krejci M; Adam Z; Pour L; Sevcikova S; Hajek R
PLoS One; 2015; 10(9):e0137294. PubMed ID: 26389804
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
